Our pipeline summarized sentences retrieved from PubMed concerning palbociclib, CDK4, and breast cancer and correctly stated that palbociclib has been approved for metastatic estrogen receptor/progesterone receptor–positive, HER2-negative breast cancer (Fig. 2A; ref. 36). This evidence concerns the gene ERBB2 and breast carcinoma.